CHICAGO (TheStreet) — An experimental antibody-drug conjugate therapy from the Genentech unit of Roche delayed by more than three months the re-growth of breast cancer compared to the current standard of care, according to a phase III study being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
The drug, known as T-DM1, will be filed for regulatory approval in the U.S. and Europe later this year, Roche said.
T-DM1 is a second-generation version of Genentech’s blockbuster breast cancer drug Herceptin. The drug consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen. …
Click to view a price quote on RHHBY.
Originally posted here: ASCO ’12: Roche, ImmunoGen Drug Delays Breast Tumor Growth
Free Penny Stock Picks